R
Robert L. Coleman
Researcher at University of Texas MD Anderson Cancer Center
Publications - 14
Citations - 3455
Robert L. Coleman is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Cancer & Ovarian cancer. The author has an hindex of 11, co-authored 14 publications receiving 2779 citations. Previous affiliations of Robert L. Coleman include University of Texas Health Science Center at Houston.
Papers
More filters
Journal ArticleDOI
Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial
Robert L. Coleman,Amit M. Oza,Domenica Lorusso,Carol Aghajanian,Ana Oaknin,Andrew Dean,Nicoletta Colombo,Johanne I Weberpals,Andrew R Clamp,Giovanni Scambia,Alexandra Leary,Robert W Holloway,Margarita Amenedo Gancedo,Peter C.C. Fong,Jeffrey C. Goh,David M. O'Malley,Deborah K. Armstrong,Jesus Garcia-Donas,Elizabeth M. Swisher,Anne Floquet,Gottfried E. Konecny,Iain A. McNeish,Clare L. Scott,Terri Cameron,Lara Maloney,Jeff Isaacson,Sandra Goble,Caroline Grace,Thomas Harding,Mitch Raponi,James Sun,Kevin K. Lin,Heidi Giordano,Jonathan A. Ledermann,Martin Buck,A Dean,Michael Friedlander,J C Goh,Paul R. Harnett,G Kichenadasse,C L Scott,H Denys,Luc Dirix,Ignace Vergote,Laurie Elit,Prafull Ghatage,Amit M. Oza,Marie Plante,Diane Provencher,J I Weberpals,Stephen Welch,A Floquet,Laurence Gladieff,Florence Joly,A Leary,Alain Lortholary,Jean-Pierre Lotz,J. Medioni,Olivier Tredan,Benoit You,A El-Balat,C Hänle,P Krabisch,T Neunhöffer,M Pölcher,Pauline Wimberger,Amnon Amit,S Kovel,M Leviov,Tamar Safra,Ronnie Shapira-Frommer,Salomon M. Stemmer,Alessandra Bologna,N Colombo,Domenica Lorusso,Sandro Pignata,Roberto Sabbatini,G Scambia,Stefano Tamberi,Claudio Zamagni,P C Fong,A O'Donnell,M Amenedo Gancedo,A Casado Herraez,J Garcia-Donas,E M Guerra,A Oaknin,I Palacio,Iris L. Romero,A Sanchez,Susana Banerjee,A Clamp,Y Drew,Hani Gabra,D Jackson,Jonathan A. Ledermann,I A McNeish,Christine Parkinson,Melanie E Powell,C Aghajanian,D K Armstrong,Michael J. Birrer,Mary K. Buss,Setsuko K. Chambers,L-m Chen,Robert L. Coleman,R W Holloway,G E Konecny,L Ma,Mark A. Morgan,R T Morris,David G. Mutch,D M O'Malley,B M Slomovitz,E M Swisher,T Vanderkwaak,M Vulfovich +116 more
TL;DR: This trial assessed rucaparib versus placebo after response to second-line or later platinum-based chemotherapy in patients with high-grade, recurrent, platinum-sensitive ovarian carcinoma harbouring a BRCA mutation or high percentage of genome-wide loss of heterozygosity.
Journal ArticleDOI
Dicer, Drosha, and outcomes in patients with ovarian cancer
William M. Merritt,Yvonne G. Lin,Liz Y. Han,Aparna A. Kamat,Whitney A. Spannuth,Rosemarie Schmandt,Diana L. Urbauer,Len A. Pennacchio,Len A. Pennacchio,Jan Fang Cheng,Jan Fang Cheng,Alpa M. Nick,Michael T. Deavers,Alexandra A. Mourad-Zeidan,Hua Wang,Peter R. Mueller,Marc E. Lenburg,Joe W. Gray,Samuel C. Mok,Michael J. Birrer,Gabriel Lopez-Berestein,Robert L. Coleman,Menashe Bar-Eli,Anil K. Sood +23 more
TL;DR: Levels of Dicer and Drosha mRNA in ovarian-cancer cells have associations with outcomes in patients with ovarian cancer, and functional assays indicated that gene silencing with shRNA, but not siRNA, may be impaired in cells with low Dicer expression.
Journal ArticleDOI
Regulation of Tumor Angiogenesis by EZH2
Chunhua Lu,Hee Dong Han,Lingegowda S. Mangala,Rouba Ali-Fehmi,Christopher S. Newton,Laurent Ozbun,Guillermo N. Armaiz-Pena,Wei Hu,Rebecca L. Stone,Adnan R. Munkarah,Murali Ravoori,Mian M.K. Shahzad,Mian M.K. Shahzad,Jeong Won Lee,Jeong Won Lee,Edna M. Mora,Edna M. Mora,Robert R. Langley,Amy R. Carroll,Koji Matsuo,Whitney A. Spannuth,Rosemarie Schmandt,Nicholas B. Jennings,Blake W. Goodman,Robert B. Jaffe,Alpa M. Nick,Hye Sun Kim,Hye Sun Kim,Eylem Güven,Ya Huey Chen,Long Yuan Li,Long Yuan Li,Ming Chuan Hsu,Robert L. Coleman,George A. Calin,Emir Baki Denkbaş,Jae Yun Lim,Ju Seog Lee,Vikas Kundra,Michael J. Birrer,Mien Chie Hung,Mien Chie Hung,Gabriel Lopez-Berestein,Anil K. Sood +43 more
TL;DR: It is shown that increased Zeste homolog 2 (EZH2) expression in either tumor cells or in tumor vasculature is predictive of poor clinical outcome, and the potential for targeting ezh2 as an important therapeutic approach is supported.
Journal ArticleDOI
Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline
Alexi A. Wright,Kari Bohlke,Deborah K. Armstrong,Michael A. Bookman,William A. Cliby,Robert L. Coleman,Don S. Dizon,Joseph J. Kash,Larissa A. Meyer,Kathleen N. Moore,Alexander B. Olawaiye,Jessica Oldham,Ritu Salani,Dee Sparacio,William P. Tew,Ignace Vergote,Mitchell I. Edelson +16 more
TL;DR: For selected women with stage IIIC or IV epithelial ovarian cancer, neoadjuvant chemotherapy and interval cytoreduction are noninferior to primary cytoreductive and adjuvant chemotherapy with respect to overall and progression-free survival and are associated with less perioperative morbidity and mortality.
Journal ArticleDOI
Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline ☆
Alexi A. Wright,Kari Bohlke,Deborah K. Armstrong,Michael A. Bookman,William A. Cliby,Robert L. Coleman,Don S. Dizon,Joseph J. Kash,Larissa A. Meyer,Kathleen N. Moore,Alexander B. Olawaiye,Jessica Oldham,Ritu Salani,Dee Sparacio,William P. Tew,Ignace Vergote,Mitchell I. Edelson +16 more
TL;DR: For selected women with stage IIIC or IV epithelial ovarian cancer, neoadjuvant chemotherapy and interval cytoreduction are non-inferior to primary cytoreductive and adjuvant chemotherapy with respect to overall and progression-free survival and are associated with less perioperative morbidity and mortality.